Prelude Therapeutics Incorporated

What they do

Prelude discovers and develops new chemical entities against cancer targets with high unmet need, using medicinal chemistry and cancer biology capabilities built since its 2016 inception. Its pipeline spans kinases, targeted protein degraders, and DACs, and it has received FDA IND clearances for multiple programs. It runs clinical development itself and also works with partners such as AbCellera and Incyte.

Revenue drivers

• JAK2V617F inhibitor program (Incyte option) — Incyte holds an exclusive option to acquire the mutant-selective JAK2V617F program for $100 million, with up to $775 million in additional clinical and regulatory milestones and single-digit royalties; total potential cash payments excluding royalties could reach up to $910 million.
• PRT12396 (lead JAK2V617F inhibitor) — Received FDA IND clearance in February 2026 and is currently enrolling a Phase 1 study in polycythemia vera and myelofibrosis; this program is the subject of the Incyte option.
• KAT6A degrader program (PRT13722) — Lead KAT6A degrader, presented preclinical data at AACR 2026; Phase 1 study in HR+/HER2- breast cancer expected to begin in the fourth quarter of 2026 pending IND clearance.
• mCALR degrader antibody conjugate (DAC) program — Wholly owned and controlled discovery program targeting mutant calreticulin in myelofibrosis and essential thrombocythemia; preclinical data presented at EHA 2025 and ASH 2025, with lead development candidates being advanced.

Recent performance

Prelude reported second quarter 2026 revenue of $5.7 million, following $4.6 million in the first quarter of 2026, $5.6 million in the fourth quarter of 2025 and $6.5 million in the third quarter of 2025. Full-year 2025 revenue was $12.1 million versus $7.0 million in 2024, while the net loss narrowed to $99.5 million in 2025 from $127.2 million in 2024. Operating cash use fell to $56.3 million in 2025 from $102.9 million in 2024. At June 30, 2026, the company reported total assets of $189.4 million, total liabilities of $55.6 million and shareholder equity of $133.7 million.

Strategy

Management's stated objective is to become a fully integrated oncology company built on internal drug discovery, advancing first- or best-in-class candidates in indications with limited or no approved options. Near-term priorities are initiating the PRT13722 Phase 1 study in HR+ breast cancer in the fourth quarter of 2026, continuing enrollment in the PRT12396 Phase 1 study in PV and MF, and advancing lead candidates from the mCALR DAC program. The company advances the JAK2V617F program toward predefined milestones under its exclusive option agreement with Incyte. It also pursues partnered discovery work, including the early-stage antibody-degrader program with AbCellera.

Risks

• No product revenue, history of losses — Prelude has incurred significant operating losses since inception, including a $99.5 million net loss in 2025, and expects continued losses for the foreseeable future.
• Need for substantial additional funding — Because the company does not currently generate product revenue, it depends on working capital and will need to raise substantial additional capital, or it may have to delay, reduce or eliminate programs.
• Early-stage, unapproved pipeline — Its product candidates are in early development; it has not completed late-stage pivotal trials or obtained regulatory approval for any candidate, and may never do so.
• Dependence on partner options and milestones — Potential JAK2V617F economics depend on Incyte exercising its exclusive option and on achieving clinical and regulatory milestones, which are uncertain and outside Prelude's sole control.

Outlook

Management expects to initiate the Phase 1 study of PRT13722 in HR+ breast cancer in the fourth quarter of 2026, pending IND clearance, and to continue enrolling the PRT12396 Phase 1 study in PV and MF. Cash, cash equivalents, restricted cash and marketable securities of $155 million as of June 30, 2026 are expected to fund operations into the second quarter of 2028.